Increase in cases of kidney disorders is expected to propel the growth of the global reperfusion treatment market. For instance, according to an article published in the Kidney International Journal, in 2015, delayed graft function (DGF) is a common complication that is observed in patients who had kidney transplants. According to the same source, DGF incidence ranges from 20% to 50% when the kidney is transplanted from a deceased donor, while there are around 4% to 10% incidence from kidney of a living donor.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4248
Moreover, increasing prevalence of chronic mesenteric ischemia (CMI) is also expected to boost growth of the global reperfusion treatment market. For instance, according to the National Centre for Biotechnology Information (NCBI), 2020, around 10% of the global population over the age of 65 years is suffering from CMI, a peripheral vascular disease. CMI is predominantly observed in females than males and mostly in the age group of 50-70 years.
The global reperfusion treatment market is expected to exhibit a CAGR of 4.5% during the forecast period (2020–2027)
R&D of new therapies is expected to offer lucrative growth opportunities for players in the global reperfusion treatment market. For instance, in 2015, Stealth BioTherapeutics Inc. conducted clinical trials to study the safety and efficacy of its lead product candidate, Bendavia (MTP-131) in reducing the reperfusion injury in patients with acute coronary syndrome (ACS). The clinical trial showed positive results for Bendavia (MTP-131) which can be used for managing the reperfusion injury with ACS.
Emergence of covid-19 has led to halt in clinical trials. In April 2020, 63 percent of survey respondents announced that they had stopped recruiting new patients for ongoing clinical trials and 43% of the respondents had postponed their studies, according to a survey conducted by Medidata Solutions, Inc. (a U.S.-based technology company that develops and markets software as a service for clinical trials).
Major players in the global reperfusion treatment market are focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in September 2020, Corline Biomedical AB signed a development agreement with the University Healthcare Network, Canada, to initiate preclinical trials for evaluating the safety and efficacy of the Renaparin during lung transplantation.
Major players operating in the reperfusion treatment market are Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V., Balmes Transplantation SAS, Revive Therapeutics Ltd., Faraday Pharmaceuticals, Radikal Therapeutics Inc., Amyndas Pharmaceuticals, Perfusion.com, Inc., Angion Biomedica Corp., Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc., and Bolder Bio Technology Inc.
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/4248
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027